Salute e Benessere

Electrostatic Discharge (ESD) Packaging Market Size to Grow USD 7.1 Billion by…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/ALLI-Auto-3O562/Electrostatic_Discharge_ESD_Packaging Claim Your Free Sample Now:https://reports.valuates.com/request/sample/ALLI-Auto-3O562/Electrostatic_Discharge_ESD_Packaging Major Factors Driving the Growth of the EDS Packaging Market The market for Easy Dispensing Systems (EDS) packaging is expanding due to rising customer demand for practical and easy-to-use packaging alternatives as well as...
PR Newswire
07/02/2024

Cardiology Information Systems: Enhancing Cardiovascular Care and Driving Market…

Request Exclusive Sample Report: Cardiology Information Systems Industry Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-18946 Request Exclusive Sample Report: Cardiology Information Systems Industry Strategic Insights,https://www.futuremarketinsights.com/reports/sample/rep-gb-18946 The growing occurrence of cardiovascular diseases on a global scale has generated a heightened demand for sophisticated solutions to effectively organize and streamline data...
PR Newswire
07/02/2024

Essity included in S&P Global's Sustainability Yearbook 2024

"Every day, over a billion people use our products, services and solutions. Thanks to responsible business practice throughout the value chain and breakthrough innovations, Essity and our customers are reducing the environmental footprint. Happy to see this important work being recognized," says Magnus Groth, President and CEO of Essity. "Every day, over a billion people use our products, services and solutions. Thanks to responsible business practice throughout the value chain…
PR Newswire
07/02/2024

Sectra continues its winning streak of global customer satisfaction with 5 Best…

"These awards showcase our excellent employees who continuously go above and beyond to meet customer needs. Over the past year, we have restructured our organization into teams to ensure consistent and knowledgeable guidance throughout the sales, implementation, and support phases of the customer journey. This, along with product offerings that reduce IT costs, increase security, and grow with our users' enterprise imaging requirements, has solidified our success," says Marie Ekström…
PR Newswire
07/02/2024

Fapon at Medlab Middle East 2024: Advancing Local Healthcare through IVD…

Highlighting its one-stop CLIA solution, Fapon's exhibition will nonetheless feature the latest ultra-high throughput CLIA system, Shine i8000/9000, which is widely recognized for its efficiency and speedy results. This addition, complementing the existing Shine i1000 and Shine i2000, completes Fapon's instrument portfolio, provides a comprehensive range of high, medium, and low-throughput CLIA instruments. This ensures a more extensive and flexible range of choices for its IVD partners. ...
PR Newswire
07/02/2024

Therabody Bolsters Leadership to Drive Ambitious Growth Plans

"Mike and Peter bring years of experience, success, and outsized value creation in sales and operations across multiple industries, including Consumer Electronics," said Monty Sharma, CEO and President of Therabody. Expressing his enthusiasm for this strategic move, he added, "We are excited to have them join our excellent Therabody team and supercharge the pursuit of our purpose." "Mike and Peter bring years of experience, success, and outsized value creation in sales…
PR Newswire
07/02/2024

Pancreatic Cancer Treatments Poised for Major Advances in 2024

After closing out 2022 with another fast track designation, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer. This recognition came after pelareorep plus atezolizumab with gemcitabine and nab-paclitaxel achieved an impressive objective response rate (ORR) of 69%. The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the…
PR Newswire
07/02/2024

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). The Notification Letter confirmed that the closing bid...
Nasdaq GlobeNewswire
07/02/2024

Enable Injections Appoints David Kroekel as Chief Operating Officer

"David brings a wealth of experience in cross-functional collaboration, infrastructure development, and engineering excellence in medical device manufacturing and development," said Mike Hooven, Chairman and CEO of Enable Injections. "In the past year, Enable has poised itself for long-term commercial success and increasing product demand – with the U.S. FDA approval of the Company's first enFuse combination product, and three high-value collaborations with both new and existing…
PR Newswire
07/02/2024

Theriva Biologics Announces Positive Recommendation from the Independent Data…

The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track to complete enrollment in the first half of 2024 /nab-paclitaxel) as a first-line therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). According to the IDMC's comprehensive assessment of clinical data from patients enrolled across 6 sites open in the U.S. and 9 sites open in Spain, the ongoing Phase 2b trial will continue...
Nasdaq GlobeNewswire
07/02/2024

Essity included in S&P Global's Sustainability Yearbook 2024

"Every day, over a billion people use our products, services and solutions. Thanks to responsible business practice throughout the value chain and breakthrough innovations, Essity and our customers are reducing the environmental footprint. Happy to see this important work being recognized," says Magnus Groth, President and CEO of Essity. "Every day, over a billion people use our products, services and solutions. Thanks to responsible business practice throughout the value chain…
PR Newswire
07/02/2024

SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer…

The program from SOPHiA GENETICS and AstraZeneca Spain started in 2022, when AstraZeneca and SOPHiA GENETICS collaborated to deploy HRD testing to five labs throughout the country. In just six weeks on average, the labs were ready to start processing samples, allowing them to process tumor samples in an expedient manner. This collaboration allowed for over 4,000 samples to be analyzed to-date, equating to approximately 90 percent of HRD testing available for patients in Spain. The program…
PR Newswire
07/02/2024

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for…

Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition. In ARDS patients, cytokines - a type of inflammatory protein - are released bringing neutrophils to the lung to fight infection. These proteins, however, can leak into blood vessels, traveling through the body resulting in inflammation of other organs which may lead to organ failure. Clinically, patients with viral respiratory infections can develop…
PR Newswire
07/02/2024

Medical Electronics Market to Reach $23.0 Billion, Globally, by 2032 at 6.73%…

Download Research Report Sample & TOC: https://www.alliedmarketresearch.com/request-sample/1034(We look forward to moving quickly provide the report analysis as per your research requirement, needed for your business success.) Download Research Report Sample & TOC: https://www.alliedmarketresearch.com/request-sample/1034(We look forward to moving quickly provide the report analysis as per your research requirement, needed for your business success.) Prime determinants of...
PR Newswire
07/02/2024

CACI Earns Coveted UKAS Accreditation for ISO/IEC 17025:2017, Strengthening…

CACI's digital forensics laboratory, situated in Northallerton, North Yorkshire, has been designed to match the capabilities of law enforcement digital forensic laboratories. This enables CACI to integrate seamlessly with their clients, minimising the impact of outsourcing digital forensic investigation services and maximising the benefit for the client. The team behind the laboratory consists of highly skilled professionals with extensive experience in the digital forensics field within Law…
PR Newswire
07/02/2024

Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of Lead…

The study is investigating the safety and tolerability of lead product, H-Guard, in patients undergoing haemodialysis (HD) who are vulnerable to dialysis-induced immune activation. Immune activation occurs when a patient's blood comes into contact with foreign surfaces in the dialysis circuit, which can result in excessive inflammation, coagulation, vascular and organ damage and other adverse consequences. H-Guard is flushed through the dialysis machine prior to commencing treatment and aims to…
PR Newswire
07/02/2024

Biocomposites announces two new Phase II clinical trials of STIMULAN VG - a…

Biocomposites is now recruiting patients to its BLADE-VG2 trial, which will evaluate the safety and efficacy of STIMULAN VG in treating diabetic foot osteomyelitis. In addition, Biocomposites will shortly be commencing its BLADE-OPU2 trial, which will investigate the safety and efficacy of STIMULAN VG in treating stage IV pressure ulcers. Biocomposites is now recruiting patients to its BLADE-VG2 trial, which will evaluate the safety and efficacy of STIMULAN VG in treating diabetic foot…
PR Newswire
07/02/2024

SmartCella obtains approval for GMP manufacturing and quality control testing of…

Alden Kandic, Head of Quality and Qualified Person at ProCella, says: "We are immensely proud of this important milestone. This world-class GMP facility will enable us to manufacture according to cGMP for clinical studies. The 300 square meter facility, built in 2022, consists of two large grade B cleanrooms, and one grade C and D room, respectively. Over the last year, the team conducted comprehensive validation activities of both the facility and equipment. Furthermore, we have…
PR Newswire
07/02/2024

VALNEVA: Declaration of shares and voting rights - January 31, 2024

VALNEVADeclaration of shares and voting rightsJanuary 31, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: February 7, 2024Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* ...
Nasdaq GlobeNewswire
07/02/2024

119,021 Orion Corporation A shares converted into B shares

ORION CORPORATIONSTOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 7 FEBRUARY 2024 at 9.30 EEST 119,021 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 119,021 A shares have been converted into 119,021 B shares. The conversion has been entered into the Trade Register on 7 February 2024.The total number of shares in Orion Corporation is 141,134,278...
Nasdaq GlobeNewswire
07/02/2024

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report…

"We have high expectations for the launch of MOB-015 - the first topical medication with an equivalent antifungal effect to tablets but without the risk of serious side effects. The goal is the same as last time, to achieve a market-leading position", says Mimmi Frölén, CEO of Allderma AB. " We have high expectations for the launch of MOB-015 - the first topical medication with an equivalent antifungal effect to tablets but without the risk of serious side effects. The goal is the…
PR Newswire
07/02/2024

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire…

DUBLIN and ALDERLEY PARK, United Kingdom, Feb. 7, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat sarcoma virus) inhibitor program. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities.
PR Newswire
07/02/2024

Monthly information related to total number of voting rights and shares…

Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing markets:Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) &Nasdaq Global Select Market in the United-States (Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)voting rightsTotal of net(2)voting rights December 31, 20236 075 1056 226 9826 226 733...
Nasdaq GlobeNewswire
06/02/2024

Digital Biomarkers Market to Worth $8.58 Billion by 2029, Increasing Adoption of…

Browse In-depth TOC on the Global Digital Biomarkers Market Browse In-depth TOC on the Global Digital Biomarkers Market 352– Pages 174 - Tables 113 - Figures Digital Biomarkers Market Report Scope The increasing focus on drug development using digital biomarkers has reshaped the global pharmaceutical industry. As the healthcare sector continues to embrace data-driven solutions and precision medicine, digital biomarkers provide a valuable tool to enhance...
PR Newswire
06/02/2024
Altri  Comunicati